TELA Bio, Inc. Appoints Bruce Freedman as Vice President of Clinical Development
January 05, 2021 at 07:00 am EST
Share
TELA Bio, Inc. announced that it has welcomed Bruce Freedman, M.D., FACS as Vice President of Clinical Development. After 32 years as a private practice general surgeon specializing in hernia repair and abdominal wall reconstruction, Dr. Freedman has joined TELA Bio to advocate for a more natural hernia repair mesh option as an alternative to permanent and resorbable synthetic mesh. In his role, Dr. Freedman will be using his extensive experience as a healthcare provider to share the clinical and financial benefits of the OviTex Reinforced Tissue Matrix portfolio with surgeons and hospital administration.
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patientâs own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO, INC. 
